Eliglustat

Eliglustat
Systematic (IUPAC) name

N-[(1R,2R)-1-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(1-pyrrolidinyl)-2-propanyl]octanamide
Clinical data
Trade names	Cerdelga
Legal status	US: ℞-only
Identifiers
CAS Registry Number	491833-29-5
ATC code	A16AX10
PubChem	CID 23652731
ChemSpider	28475348
ChEBI	CHEBI:82752^Y
Chemical data
Formula	C₂₃H₃₆N₂O₄
Molecular mass	404.543 g/mol
SMILES CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@@H](C2=CC3=C(C=C2)OCCO3)O
InChI InChI=1S/C23H36N2O4/c1-2-3-4-5-6-9-22(26)24-19(17-25-12-7-8-13-25)23(27)18-10-11-20-21(16-18)29-15-14-28-20/h10-11,16,19,23,27H,2-9,12-15,17H2,1H3,(H,24,26)/t19-,23-/m1/s1 Key:FJZZPCZKBUKGGU-AUSIDOKSSA-N

Eliglustat (INN, USAN;^[1] trade name Cerdelga) is a treatment for Gaucher's disease developed by Genzyme Corp that was approved by the FDA August 2014.^[2] Commonly used as the tartrate salt, the compound is believed to work by inhibition of glucosylceramide synthase.^[3]^[4]

References

↑ https://download.ama-assn.org/resources/doc/usan/x-pub/eligustat.pdf
↑ http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm410585.htm
↑ Lee, L.; Abe, A.; Shayman, J. A. (21 May 1999). "Improved Inhibitors of Glucosylceramide Synthase". Journal of Biological Chemistry 274 (21): 14662–14669. doi:10.1074/jbc.274.21.14662.
↑ Shayman, JA (Aug 1, 2010). "ELIGLUSTAT TARTRATE: Glucosylceramide Synthase Inhibitor Treatment of Type 1 Gaucher Disease.". Drugs of the future 35 (8): 613–620. PMID 22563139. |accessdate= requires |url= (help)

Other alimentary tract and metabolism products (A16)

Amino acids and derivatives

Other

Index of digestion

Description	Anatomy tract glands other Physiology enzymes Development

Disease	Congenital Neoplasms and cancer Inflammatory bowel disease Gluten sensitivity Other Symptoms and signs eponymous Blood tests

Treatment	Procedures Drugs anabolic steroids antacids diarrhoea and infection bile and liver functional gastrointestinal disorders laxatives peptic ulcer and reflux nausea and vomiting other Surgery